Benjamin Machinas Beneski net worth and biography

Benjamin Beneski Biography and Net Worth

Ben Beneski is the Senior Vice President and Chief Technical Officer of Allogene. With a career spanning more than two decades in biologics manufacturing and technical operations, Ben brings a wealth of experience and strategic vision to Allogene. He joined Allogene in 2019 as Executive Director and Plant Manager, where he played a pivotal role in the design, construction, and successful startup of Cell Forge 1, the company’s cutting-edge manufacturing facility. During his time at Allogene, Ben has advanced through a series of increasingly senior roles, including Vice President of Manufacturing and Vice President of Product Development and Manufacturing where he led the development of next-generation platforms, effectively managed internal and external manufacturing networks, and drove key initiatives to support IND submissions and ensure commercial readiness. Prior to joining Allogene, Ben held senior manufacturing roles at various biotechnology companies, including Vir Biotechnology and Amgen. He holds a Master’s in Business Administration from Northeastern University and a Bachelor’s Degree in Chemical Engineering from Stevens Institute of Technology.

What is Benjamin Machinas Beneski's net worth?: The estimated net worth of Benjamin Machinas Beneski is at least $496.50 thousand as of March 16th, 2026. Beneski owns 198,205 shares of Allogene Therapeutics stock worth more than $496,504 as of March 23rd. This net worth evaluation does not reflect any other assets that Beneski may own. Learn More about Benjamin Machinas Beneski's net worth.
How do I contact Benjamin Machinas Beneski?: The corporate mailing address for Beneski and other Allogene Therapeutics executives is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Allogene Therapeutics can also be reached via phone at (650) 457-2700 and via email at [email protected]. Learn More on Benjamin Machinas Beneski's contact information.
Has Benjamin Machinas Beneski been buying or selling shares of Allogene Therapeutics?: During the last quarter, Benjamin Machinas Beneski has sold $43,545.42 in Allogene Therapeutics stock. Most recently, Benjamin Machinas Beneski sold 4,835 shares of the business's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $2.47, for a transaction totalling $11,942.45. Following the completion of the sale, the senior vice president now directly owns 198,205 shares of the company's stock, valued at $489,566.35. Learn More on Benjamin Machinas Beneski's trading history.
Who are Allogene Therapeutics' active insiders?: Allogene Therapeutics' insider roster includes Rafael Amado (CMO), Arie Belldegrun (Director), Benjamin Beneski (SVP), Veer Bhavnagri (General Counsel), David Chang (President, Chief Executive Officer and Co-Founder), Earl Douglas (SVP), Franz Humer (Director), Stephen Mayo (Director), Geoffrey Parker (Executive Vice President, Chief Financial Officer), Zachary Roberts (Executive Vice President, Research & Development, Chief Medical Officer), Owen Witte (Director), and Annie Yoshiyama (SVP). Learn More on Allogene Therapeutics' active insiders.
Are insiders buying or selling shares of Allogene Therapeutics?: During the last year, insiders at the sold shares 12 times. They sold a total of 321,930 shares worth more than $586,720.72. The most recent insider tranaction occured on March, 16th when SVP Benjamin Machinas Beneski sold 4,835 shares worth more than $11,942.45. Insiders at Allogene Therapeutics own 13.2% of the company. Learn More about insider trades at Allogene Therapeutics.
Information on this page was last updated on 3/16/2026.

Benjamin Machinas Beneski Insider Trading History at Allogene Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/16/2026	Sell	4,835	$2.47	$11,942.45	198,205
3/2/2026	Sell	7,132	$2.60	$18,543.20	203,040
2/2/2026	Sell	7,549	$1.73	$13,059.77	210,172
3/14/2025	Sell	5,488	$1.98	$10,866.24	218,507

Benjamin Machinas Beneski Buying and Selling Activity at Allogene Therapeutics

Allogene Therapeutics Company Overview

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Today's Range

Now: $2.54

$2.13

$2.60

50 Day Range

MA: $2.01

$1.45

$2.78

2 Week Range

Now: $2.54

$0.86

$2.80

Volume

8,572,875 shs

Average Volume

5,965,387 shs

Market Capitalization

$617.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.5